Should I buy or sell Biora Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOR shares. View BIOR analyst ratings or view top-rated stocks .

How have BIOR shares performed in 2023?

Biora Therapeutics' stock was trading at $82.3125 at the start of the year. Since then, BIOR shares have decreased by 98.4% and is now trading at $1.35. View the best growth stocks for 2023 here .

Are investors shorting Biora Therapeutics?

Biora Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 653,700 shares, an increase of 28.6% from the October 31st total of 508,200 shares. Based on an average daily volume of 166,500 shares, the days-to-cover ratio is currently 3.9 days. Currently, 2.9% of the company's stock are short sold. View Biora Therapeutics' Short Interest .

When is Biora Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our BIOR earnings forecast .

How were Biora Therapeutics' earnings last quarter?

Biora Therapeutics, Inc. (NASDAQ:BIOR) announced its earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.01. The firm had revenue of $0.18 million for the quarter, compared to analyst estimates of $11.10 million. During the same quarter last year, the firm earned ($1.01) earnings per share.

When did Biora Therapeutics' stock split?

Biora Therapeutics shares reverse split on the morning of Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Biora Therapeutics' major shareholders?

Biora Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Sabby Management LLC (2.71%), Group One Trading L.P. (0.00%), Cutler Group LLC CA (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Athyrium Capital Management, L, Damon Silvestry, Harry Stylli, Jeffrey D Alter and Surbhi Sarna. View institutional ownership trends .

How do I buy shares of Biora Therapeutics?

Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Biora Therapeutics Stock Price, News & Analysis (NASDAQ:BIOR)

$1.35

+0.11 (+8.87%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.24
▼
$1.61
50-Day Range: $1.21
▼
$2.62
52-Week Range: $1.18
▼
$7.68

Volume: 12.23 million shs
Average Volume: 442,928 shs
Market Capitalization: $32.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Biora Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.55) to ($2.06) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.37 out of 5 stars

Medical Sector

901st out of 954 stocks

Pharmaceutical Preparations Industry

419th out of 439 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Biora Therapeutics.

3.0

Short Interest

Percentage of Shares Shorted
2.92% of the float of Biora Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Biora Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biora Therapeutics has recently increased by 28.63%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biora Therapeutics does not currently pay a dividend.
Dividend Growth
Biora Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BIOR.

2.3

News and Social Media Coverage

News Sentiment
Biora Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Biora Therapeutics this week, compared to 2 articles on an average week.
Search Interest
7 people have searched for BIOR on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Biora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biora Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.18% of the stock of Biora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 24.79% of the stock of Biora Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biora Therapeutics are expected to grow in the coming year, from ($4.55) to ($2.06) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biora Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biora Therapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Biora Therapeutics Stock (NASDAQ:BIOR)

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

BIOR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIOR Stock News Headlines

December 1, 2023 | msn.com

FDA clears IND for Biora Therapeutics’s ulcerative colitis drug

December 1, 2023 | msn.com

Why Is Chronic Disease Focused Biora Therapeutics Stock Trading Higher Today?

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 30, 2023 | markets.businessinsider.com

FDA Clears Biora's IND Application For BT-600 In Ulcerative Colitis Treatment; Stock Surges

November 30, 2023 | marketwatch.com

Biora Therapeutics Application for Ulcerative Colitis Treatment Gets FDA Clearance

November 30, 2023 | msn.com

FDA clears Biora to begin Phase 1 testing of ulcerative colitis treatment

November 30, 2023 | marketwatch.com

Biora Therapeutics Shares Rise 64% After FDA Clears Application for Ulcerative Colitis Treatment

November 30, 2023 | finance.yahoo.com

Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 16, 2023 | finanznachrichten.de

Biora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 14, 2023 | msn.com

BIOR: 3Q:23 Results

November 14, 2023 | finance.yahoo.com

Biora Therapeutics, Inc. (NASDAQ:BIOR) Q3 2023 Earnings Call Transcript

November 14, 2023 | finance.yahoo.com

Q3 2023 Biora Therapeutics Inc Earnings Call

November 13, 2023 | finance.yahoo.com

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 13, 2023 | msn.com

Biora Therapeutics GAAP EPS of -$4.89 misses by $3.96

November 13, 2023 | benzinga.com

Recap: Biora Therapeutics Q3 Earnings

November 13, 2023 | finance.yahoo.com

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 12, 2023 | markets.businessinsider.com

Biora Therapeutics earnings: here's what Wall Street expects

November 10, 2023 | benzinga.com

Earnings Outlook For Biora Therapeutics

November 6, 2023 | finance.yahoo.com

Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update

November 1, 2023 | markets.businessinsider.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIOR

October 31, 2023 | finanznachrichten.de

Biora Therapeutics, Inc.: Biora Therapeutics Submits Updated IND Application for BT-600

October 30, 2023 | msn.com

Biora submits updated IND application to FDA for BT-600

October 30, 2023 | finance.yahoo.com

Biora Therapeutics Submits Updated IND Application for BT-600

October 24, 2023 | msn.com

Biora submits updated IND application for ulcerative colitis drug/device trial

October 23, 2023 | msn.com

Biora IND for BT-600 delayed due to FDA request for more info

October 23, 2023 | finance.yahoo.com

Biora Therapeutics to Submit Updated IND Application for BT-600

See More Headlines

Receive BIOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BIOR
CUSIP: N/A
CIK: 1580063
Web: www.bioratherapeutics.com
Phone: 833-727-2841
Fax: N/A
Employees: 54
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($9.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,160,000.00
Net Margins: -55,269.39%
Pretax Margin: -677,261.06%
Return on Equity: N/A
Return on Assets: -125.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.28
Quick Ratio: 0.28

Sales & Book Value

Annual Sales: $310,000.00
Price / Sales: 103.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($5.01) per share
Price / Book: -0.27

Miscellaneous

Outstanding Shares: 23,700,000
Free Float: 18,209,000
Market Cap: $32.00 million
Optionable: Optionable
Beta: 1.22

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Aditya P. Mohanty M.B.A. (Age 56)
CEO & Director
Comp: $858.82k
Mr. Eric d'Esparbes (Age 55)
Executive VP & CFO
Comp: $651.91k
Mr. Clarke Neumann J.D. (Age 59)
Senior VP, General Counsel & Secretary
Comp: $624.13k
Eric Fox
VP of Finance & Accounting & Treasurer
Mr. Troy Seelye (Age 59)
Chief Information Officer
Mr. George Gianakopoulos (Age 62)
Senior Vice President of Sales
Ms. Robyn Hatton
Head of Human Resources
Mr. Kevin Howe Ph.D.
Senior VP of Strategic Operations
Dr. Sharat Singh Ph.D. (Age 64)
Head of Research
Dr. Paul Shabram M.B.A.
Head of Technical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BIOR Stock Analysis - Frequently Asked Questions

Should I buy or sell Biora Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOR shares.
View BIOR analyst ratings or view top-rated stocks.
How have BIOR shares performed in 2023?: Biora Therapeutics' stock was trading at $82.3125 at the start of the year. Since then, BIOR shares have decreased by 98.4% and is now trading at $1.35.
View the best growth stocks for 2023 here.
Are investors shorting Biora Therapeutics?: Biora Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 653,700 shares, an increase of 28.6% from the October 31st total of 508,200 shares. Based on an average daily volume of 166,500 shares, the days-to-cover ratio is currently 3.9 days. Currently, 2.9% of the company's stock are short sold.
View Biora Therapeutics' Short Interest.
When is Biora Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our BIOR earnings forecast.

How were Biora Therapeutics' earnings last quarter?: Biora Therapeutics, Inc. (NASDAQ:BIOR) announced its earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.01. The firm had revenue of $0.18 million for the quarter, compared to analyst estimates of $11.10 million. During the same quarter last year, the firm earned ($1.01) earnings per share.
When did Biora Therapeutics' stock split?: Biora Therapeutics shares reverse split on the morning of Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
Who are Biora Therapeutics' major shareholders?: Biora Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Sabby Management LLC (2.71%), Group One Trading L.P. (0.00%), Cutler Group LLC CA (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Athyrium Capital Management, L, Damon Silvestry, Harry Stylli, Jeffrey D Alter and Surbhi Sarna.
View institutional ownership trends.
How do I buy shares of Biora Therapeutics?: Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BIOR) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial